Anne K. Wouters

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.

Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.

Journal: Journal of ovarian research

Published: February 23, 2026

Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.

Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.

Journal: Journal of ovarian research

Published: February 23, 2026

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.

Journal: Blood

Published: December 09, 2025

Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody.

Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody.

Journal: Oncoimmunology

Published: May 27, 2025

TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer.

TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer.

Journal: Cancer immunology research

Published: January 14, 2025

DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets.

DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets.

Journal: Molecular therapy. Oncology

Published: August 28, 2024

Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy.

Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy.

Journal: Journal for immunotherapy of cancer

Published: June 07, 2024

CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.

CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: May 08, 2024

Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.

Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.

Journal: Frontiers in immunology

Published: January 10, 2024

Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapy.

Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapy.

Journal: Molecular therapy oncolytics

Published: November 03, 2023

Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma.

Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma.

Journal: Blood advances

Published: April 07, 2023

High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs.

High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs.

Journal: The Journal of biological chemistry

Published: February 15, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026